Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endostar + carboplatin + fluorouracil is a combination regimen used in the treatment of advanced solid tumors and certain cancers such as head and neck cancer and pancreatic neuroendocrine tumors. - **Endostar** (recombinant human endostatin) is an anti-angiogenic agent that inhibits tumor blood vessel formation by targeting multiple pathways involved in angiogenesis. It is a proteolytic fragment of collagen XVIII with antitumor activity and a favorable toxicity profile[1][2]. - **Carboplatin** is an organoplatinum alkylating agent that induces DNA crosslinking leading to apoptosis in rapidly dividing cells[5]. - **Fluorouracil (5-FU)** is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and function. This combination has demonstrated moderate efficacy with tolerable toxicity profiles in clinical studies for various advanced solid tumors including head and neck cancer and pancreatic neuroendocrine tumors[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on endostar + carboplatin + fluorouracil.